Mark K.  Oki net worth and biography

Mark Oki Biography and Net Worth

Mr. Oki has served as our Chief Financial Officer since December 2024. From January 2022 to November 2024, Mr. Oki served as Chief Financial Officer of Aytu Biopharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. From 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC (formerly Vivus Inc.), a commercial-stage pharmaceutical company formerly listed on Nasdaq. From 2006 to 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation), both life sciences companies. Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).

What is Mark K. Oki's net worth?

The estimated net worth of Mark K. Oki is at least $706.23 thousand as of September 18th, 2025. Mr. Oki owns 127,940 shares of Achieve Life Sciences stock worth more than $706,229 as of June 11th. This net worth evaluation does not reflect any other assets that Mr. Oki may own. Learn More about Mark K. Oki's net worth.

How do I contact Mark K. Oki?

The corporate mailing address for Mr. Oki and other Achieve Life Sciences executives is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. Achieve Life Sciences can also be reached via phone at (604) 210-2217 and via email at [email protected]. Learn More on Mark K. Oki's contact information.

Has Mark K. Oki been buying or selling shares of Achieve Life Sciences?

Mark K. Oki has not been actively trading shares of Achieve Life Sciences during the last ninety days. Most recently, Mark K. Oki sold 50,060 shares of the business's stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $2.92, for a transaction totalling $146,175.20. Following the completion of the sale, the chief financial officer now directly owns 127,940 shares of the company's stock, valued at $373,584.80. Learn More on Mark K. Oki's trading history.

Who are Achieve Life Sciences' active insiders?

Achieve Life Sciences' insider roster includes John Bencich (CEO), Mark Oki (CFO), and Richard Stewart (CEO). Learn More on Achieve Life Sciences' active insiders.

Are insiders buying or selling shares of Achieve Life Sciences?

During the last twelve months, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 381,972 shares worth more than $1,084,996.59. The most recent insider tranaction occured on September, 18th when CFO Mark K Oki sold 50,060 shares worth more than $146,175.20. Insiders at Achieve Life Sciences own 3.0% of the company. Learn More about insider trades at Achieve Life Sciences.

Information on this page was last updated on 9/18/2025.

Mark K. Oki Insider Trading History at Achieve Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2025Sell50,060$2.92$146,175.20127,940View SEC Filing Icon  
3/17/2025Buy10,000$2.89$28,900.0010,000View SEC Filing Icon  
See Full Table

Mark K. Oki Buying and Selling Activity at Achieve Life Sciences

This chart shows Mark K Oki's buying and selling at Achieve Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Achieve Life Sciences Company Overview

Achieve Life Sciences logo
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Read More

Today's Range

Now: $5.52
Low: $5.52
High: $6.16

50 Day Range

MA: $4.51
Low: $2.94
High: $5.99

2 Week Range

Now: $5.52
Low: $2.00
High: $6.16

Volume

2,769,326 shs

Average Volume

1,050,968 shs

Market Capitalization

$566.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27